Second-line Immunotherapy for ES-SCLC — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Second-line Immunotherapy for ES-SCLC — Stella

Recruiting

Back to Extensive Stage Small Cell Lung Cancer (ES-SCLC) trials

Not a traditional drug trial — this study doesn't follow the standard phase structure.

Trial locations(1 site)

China

Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin Municipality

Key details

Sponsor

Tianjin Medical University Cancer Institute and Hospital

Enrollment target

~30 participants

Started

February 2025

Primary completion

July 2026

Age range

18 Years and older

Last updated March 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov